XML 52 R35.htm IDEA: XBRL DOCUMENT

Revenue from contracts with customers (Tables)

12 Months Ended

Dec. 31, 2023

Summary of disaggregates revenues by major revenue streams

The following table disaggregates Teva’s revenues by major revenue streams. For additional information on disaggregation of revenues, see note 19.


	Year ended December 31, 2023
	North America		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		5,944		4,631		1,840		565		12,979
Licensing arrangements *		601		51		24		5		681
Distribution		1,577		§		38		—		1,615
Other**		2		155		56		357		570

	$	8,124	$	4,837	$	1,958	$	926	$	15,846

*	Revenues from licensing arrangements in North America segment were mainly comprised of $500 million upfront payment received in connection with the collaboration on Teva’s anti-TL1A asset. See note 2.

**	“Other” revenues in Europe segment mainly related to the sale of certain product rights.

§	Represents an amount less than $ 0.5 million.


	Year ended December 31, 2022
	North America		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		5,834		4,455		1,806		671		12,766
Licensing arrangements		139		51		19		4		212
Distribution		1,471		1		46		—		1,519
Other		8		18		33		370		428

	$	7,452	$	4,525	$	1,903	$	1,045	$	14,925


	Year ended December 31, 2021
	North America		Europe		International Markets		Other activities		Total
	(U.S.$ in millions)
Sale of goods		6,394		4,807		1,889		739		13,829
Licensing arrangements		92		50		13		4		160
Distribution		1,323		1		65		—		1,390
Other		(1)		27		65		408		500

	$	7,809	$	4,886	$	2,032	$	1,151	$	15,878

Summary of Sales Reserves and Allowances

SR&A to U.S. customers comprised approximately 65% of the Company’s total SR&A as of December 31, 2023, with the remaining balance primarily in Canada and Germany. The changes in SR&A for third-party sales for the years ended December 31, 2023 and 2022 were as follows:


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net			Rebates			Medicaid and other governmental allowances			Chargebacks			Returns			Other			Total reserves included in Sales Reserves and Allowances			Total
	(U.S.$ in millions)
Balance at January 1, 2023	$	67		$	1,575		$	663		$	991		$	455		$	66		$	3,750		$	3,817
Provisions related to sales made in current year period		354			4,015			654			7,579			264			109			12,621			12,975
Provisions related to sales made in prior periods		—			(31	)		(33	)		(54	)		17			—			(101	)		(101	)
Credits and payments		(360	)		(3,974	)		(748	)		(7,662	)		(304	)		(77	)		(12,765	)		(13,125	)
Translation differences		—			18			4			5			4			(1	)		30			30

Balance at December 31, 2023	$	61		$	1,603		$	540		$	859		$	436		$	97		$	3,535		$	3,596


	Sales Reserves and Allowances
	Reserves included in Accounts Receivable, net			Rebates			Medicaid and other governmental allowances			Chargebacks			Returns			Other			Total reserves included in Sales Reserves and Allowances			Total
	(U.S.$ in millions)
Balance at January 1, 2022	$	68		$	1,655		$	854		$	1,085		$	535		$	112		$	4,241		$	4,309
Provisions related to sales made in current year period		363			3,823			871			7,819			317			85			12,915			13,278
Provisions related to sales made in prior periods		—			(69	)		(35	)		(44	)		(3	)		(51	)		(202	)		(202	)
Credits and payments		(364	)		(3,798	)		(1,023	)		(7,861	)		(390	)		(77	)		(13,149	)		(13,513	)
Translation differences		—			(36	)		(4	)		(8	)		(4	)		(3	)		(55	)		(55	)

Balance at December 31, 2022	$	67		$	1,575		$	663		$	991		$	455		$	66		$	3,750		$	3,817